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determine the value of dynamic changes 
in NGAL levels to diff erentiate pre-renal 
and intrinsic AKI and could be valuable 
in defi ning the response to a corrective 
intervention such as fl uid resuscitation. 
 Finally, the Morrow and de Lemos 9 cri-
teria require that the absolute measured 
value should help in clinical decision mak-
ing. As an example, REDHOT (the Rapid 
Emergency Department Heart Failure 
Outpatient Trial) showed that BNP levels 
greater than 200 pg / ml in patients admit-
ted with congestive heart failure  were 
predictive of the 90-day combined event 
rate (congestive heart failure  visits and 
mortality). 14 Additional studies in larger 
cohorts will need to confi rm that the pro-
posed NGAL cutoff s of 47 and 104   g / ml 
are robust and predictive of the course for 
AKI. Determining the most effi  cient cut-
off s to establish thresholds for negative 
and positive predictive values requires 
adjudication of events and consideration 
of the clinical context wherein the bio-
markers are being measured. 11 Since pre-
renal states can occur independently of 
structural changes or concurrently with 
structural changes, thresholds may vary 
( Figure 1 ). For instance, NGAL values 
to distinguish pre-renal from intrinsic AKI 
may be very different in a patient with 
prior normal kidney function versus a 
patient suspected to have hepatorenal or 
cardiorenal syndrome, in whom the asso-
ciated comorbidities and underlying renal 
dysfunction would add more complexity. 
A combination of markers may be required 
in this situation for the best results. 
 Singer  et al. 7 have added one more piece 
to the puzzle of defi ning how we should 
best use biomarkers to manage patients 
with AKI. Th eir fi ndings highlight the need 
to develop clear defi nitions of pre-renal 
state, defi ning criteria, and the process for 
adjudication of events and use of multima-
rker combinations to improve discrimina-
tory ability. NGAL is a strong contender in 
the race for the  ‘ BNP of the kidney ’ ; how-
ever, the fi nish line is still a ways off . 
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 Th ere is a spate of interest in the role of 
microRNAs (miRNAs) in the pathogenesis 
of renal diseases. Th e miRNAs are regula-
tors of gene expression. They are short 
stretches of RNA (approximately 22 nucle-
otides long) that do not code for proteins. 
A double-stranded precursor of miRNA 
with a hairpin confi guration, called the pri-
miRNA, is transcribed by RNA polymerase 
II from a specifi c gene or from introns of a 
gene coding for protein 1 ( Figure 1 ). Pri-
miRNA is processed by an RNase type III 
endonuclease, Drosha, with the aid of a 
protein, DiGeorge syndrome critical region 
8 (DGCR8), into to an approximately 70-
nucleotide-long double-stranded form 
called the pre-miRNA. Th e pre-miRNA 
transport out of the nucleus is facilitated by 
exportin 5. In the cytoplasm, the pre-
miRNA binds to transactivation-responsive 
(TAR) RNA-binding protein, Argonaute 
(Ago) proteins, and Dicer, an RNA type III 
endonuclease, and is converted into an 
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 MicroRNAs are short noncoding RNAs that usually reduce translation of 
messenger RNAs. Changes in microRNA-192 (miR-192) are reported in 
states of renal fibrosis. New evidence supports a role for miR-192 and its 
target miR-200b / c in transforming growth factor-  1 regulation of its 
own expression and that of collagens in mesangial cells, with a possible 
role in diabetic nephropathy. As there is controversy on the role of these 
microRNAs in diabetic nephropathy, more work is needed. 
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approximately 22-nucleotide-long miRNA 
duplex. Th e duplex undergoes another step 
of processing in which one strand, called 
the passenger strand, is degraded and the 
remaining strand, called the guide strand, 
becomes a part of the miRNA-induced 
silencing complex (RISC). Th e miRNA in 
the RISC binds to roughly complementary 
sequences in the 3  untranslated regions of 
target messenger RNAs; however, a strict 
complementarity between the seed 
sequence of the miRNA (second-to-eighth 
nucleotide stretch) and the seed matching 
sequence on the messenger RNA is required 
for miRNA function. The miRNA can 
interfere with translation of the messenger 
RNA into a peptide by binding to its 3  
untranslated region or by promoting its 
degradation by stimulating deadenylation 
and digestion of its polyA tail; deadenyla-
tion is facilitated by glycine-tryptophan 
protein-182, a part of the RISC. Additional 
mechanisms by which the miRNA – Ago 
complex inhibits messenger RNA transla-
tion include competition for the messenger 
RNA cap between the Ago and eukaryotic 
initiation factor 4E (eIF4E) during the ini-
tiation phase of translation, disruption of 
formation of the 80S ribosomal complex, 
and inhibition of the elongation phase of 
translation, during which amino acids are 
added to the nascent peptide according to 
the codons present in the messenger RNA. 2 
Th e eff ect of miRNA on gene expression is 
not always negative; there are examples of 
miRNAs promoting translation. 3 An indi-
vidual miRNA can aff ect the expression of 
several messenger RNAs; thus, miRNAs are 
not very specifi c. It is important to note that 
reduction in the target protein expression 
by the action of a single miRNA is rather 
modest. Th us, in most cases, an abnormal 
phenotype is due to combined eff ects of 
several miRNAs and miRNA-independent 
processes. In view of the importance of pro-
tein synthesis in the pathogenesis of kidney 
diseases characterized by hypertrophy 
and / or renal fi brosis, it is logical that inves-
tigations be directed to the role of miRNAs 
in progressive renal injury. 
 Progressive renal disease is character-
ized by renal fi brosis due to the accumula-
tion of extracellular matrix proteins in 
which growth factors play an important 
role, including transforming growth 
factor-  1 (TGF-  1). TGF-  1 can exert its 
eff ect on matrix synthesis both directly 
and via other mediators. Th e mechanism 
of sustained expression and actions of 
TGF-  1 in disease states such as diabetes 
is not fully understood. It is known that 
pathologic stimuli — for example, high 
glucose — promote TGF-  1 gene expres-
sion by recruiting transcription factors 
such as upstream stimulatory factor-1. 
Kato and associates 4 (this issue) set out to 
address whether TGF-  1 can regulate its 
own expression and whether this involves 
miRNAs. Th ey found a complex pathway 
in which TGF-  1 induces the expression 
of miRNA-192 (miR-192), which, in turn, 
augments the expression of miR-200b / c. 
TGF-  1 could not increase its own mes-
senger RNA expression in the presence of 
inhibitors of miR-192 and miR-200b, sug-
gesting that autoinduction of TGF-  1 
involved these miRNAs. During the early 
stages of type 1 and type 2 diabetes in mice 
(about 7 – 8 weeks of diabetes), the glomer-
ular expression of miR-200b / c was 
increased. Zeb1 (also called   -EF1) and 
Zeb2 (also called Sip-1) are E box-binding 
proteins, which repress transcription of 
genes such as type I collagen   2 chain. 
TGF-  1 reduced Zeb1 protein expression, 
and this reduction was negated by miR-
200b inhibitor, suggesting that Zeb1 
repression by TGF-  1 depends on miR-
200b. Th e likely mechanism was found to 
be an increase in miR-200b binding to the 
3  untranslated region of Zeb1 and inhib-
iting its translation. In addition to type I 
collagen   2 chain, mimics of miR-192 and 
miR-200b augmented the transcription of 
type IV collagen   1 chain. TGF-  1 inhib-
ited Zeb1 binding to the E box in its own 
promoter and that in the promoter of type 
I collagen   2 chain. Th us, TGF-  1 recruits 
miR-192 and -200b to regulate not only 
the expression of its known targets, type I 
and type IV collagen, but also its own tran-
scription. Th e observations of Kato  et al. 4 
in cultured mesangial cells were tested for 
 in vivo relevance by the subcutaneous 
administration of miR-192 antagonist 
(antigomiR-192) to mice; 6 hours later, 
antigomiR-192 caused a reduction in the 
expression of miR-200b / c, TGF-  1, and 
the above-mentioned collagen chains. 
Since miR-192 expression was also 
reduced, miR-192 appears to regulate its 
own expression. On the basis of these 
data, the authors suggest a potentially self-
perpetuating loop for TGF-  1 expression 
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and assign a key role to miR-192 in pro-
moting transcription not only of collagens 
but also of TGF-  1. Since the authors 
studied glomeruli from an early stage of 
diabetes, it is likely that their findings 
apply to renal hypertrophy and onset of 
type IV collagen and TGF-  1 expression 
in the kidney, which can occur within 
days of diabetes onset in rodents. 5 
 Th ere are dissenting reports on the role 
of miR-192 in causing renal parenchymal 
changes in diabetes. 6,7 Krupa  et al. found 
 reduction in miR-192 expression in the 
kidneys of patients with established dia-
betic nephropathy, which correlated with 
progressive renal fibrosis and a fall in 
glomerular fi ltration rate. 6 Th ese investi-
gators reported that in human proximal 
tubular epithelial cells, TGF-  1 reduced 
the expression of miR-192 and Zeb1; this 
was associated with a decrease in E-cad-
herin, and an increase in the expression of 
Zeb2, PAI-I, and vimentin. Wang  et al. 
also reported that TGF-  1 decreased miR-
192 expression in primary mesangial and 
rat proximal tubular epithelial cells in 
association with a cell type-dependent 
increase in Zeb1 and Zeb2 expression; 
miR-192 and miR-215 were shown to 
inhibit Zeb2 translation in proximal tubu-
lar epithelial cells, suggesting that TGF-
  1-induced inhibition of miR-192 leads 
to an increase in Zeb2 expression. TGF-  1 
reduced E-cadherin expression, and this 
was partially countered by miR-192 and 
miR-215 (ref.  7). Th e expression of miR-
192 and -215 was decreased in the renal 
cortex of apolipoprotein E   knockout mice 
at 10 weeks of diabetes in association with 
an increase in Zeb2 messenger RNA 
expression. 7 Th e diff erences in fi ndings on 
miR-192 among these reports ( Figure 2 ) 
may have to do with the diverse experi-
mental conditions used, including diff er-
ences in renal cell types; whether they were 
primary outgrowths, were established in 
serial passage, or were conditionally trans-
formed; the presence or absence of serum; 
use of diff erent animal models; early ver-
sus established stages of diabetic neph-
ropathy; use of isolated glomeruli versus 
renal cortical preparations; and mouse 
versus human sources of kidney tissue. It 
is important to fi nd a resolution by using 
commonly agreed-upon models of renal 
disease and by prospectively mapping the 
changes in TGF-  1, miRNAs including 
miR-192, -200b, and -215, and Zeb1 and 
Zeb2 proteins from early to late stages of 
disease, and individually in glomerular 
and tubulointerstitial compartments. 
Genetic manipulations by antigomiR 
administration or conditional cell- specifi c 
knockouts of select proteins in this cascade 
can also help resolve the apparently dispa-
rate fi ndings. 
 With the availability of agents that 
inhibit miRNAs, such as antigomiRs, miR-
NAs appear to be potential targets in renal 
fi brotic diseases. In view of the increase in 
glomerular miR-192 and miR-200b found 
by Kato  et al. , 4 is it possible to target these 
miRNAs to inhibit renal fi brosis? If the 
regulation of miR-192 is disease stage-spe-
cifi c and cell-specifi c in diabetic neph-
ropathy, as suggested in three studies, 4,6,7 
the outcome of miR-192 suppression 
 in vivo could have ameliorative eff ects on 
matrix expansion in one compartment of 
the nephron, for instance, the mesangium, 
but could aggravate matrix accumulation 
in another, for instance, the tubulointer-
stitium. Inhibition of miR-192 expression 
in the kidney has been achieved indirectly. 
Chung and associates have reported that 
TGF-  1 recruits the Smad3 signaling 
pathway to increase the expression of miR-
192 in the obstructed kidney. Th is was 
confi rmed by reduction in renal fi brosis 
and inhibition of miR-192 expression in 
Smad3 knockout mice following unilateral 
ureteral obstruction; 8 the status of miR-
200b was not examined. Oba  et al. have 
reported that although miR200b expres-
sion increases in the unilateral ureteral 
obstruction model, administration of 
miR200b ameliorated renal fi brosis, sug-
gesting there may be resistance to the 
reparative actions of endogenous miR200b 
that was overcome by external supplemen-
tation in this model. 9 In addition to the 
miRNAs discussed above, other miRNAs 
also participate in renal injury in diabetes. 
Renal miR-377 expression is increased in 
diabetes, which may be mediated in part 
by TGF-  1. miR-377 inhibits p21 / cdc42 /
 Rac1-activated kinase and superoxide 
dismutase to stimulate fi bronectin expres-
sion in the kidney. 10 miR-29c expression 
is increased in the diabetic kidney. It 
inhibits Sprouty homolog-1 and stimulates 
Rho kinase; administration of antisense 
oligo against miR-29c restored Sprouty-1 
expre ssion and ameliorated albuminuria 
and mesangial matrix expansion in dia-
betic mice. 11 
 When the studies reviewed above are 
taken together, the emerging lesson is that 
the context of the disease state being tar-
geted is important, as miRNAs operate 
only as a part of a much wider spectrum of 
pathogenic reactions. An additional issue 
in targeting miRNAs for therapeutic inter-
vention is their promiscuity in targeting 
several messenger RNAs. Neutralization 
of a miRNA can aff ect off -target messen-
ger RNAs, resulting in potential adverse 
reactions. It is clear that more investigation 
is needed in order to better understand the 
role of miRNAs in the pathogenesis of 
renal diseases and to critically evaluate 
them as therapeutic targets. 
 Figure 2  |  Role of miRNA in diabetic nephropathy. miR, miRNA; PTEC, proximal tubule 
epithelial cells; T1D, type 1 diabetes; T2D, type 2 diabetes; TGF-  1, transforming growth factor-  1. 
Arrows indicate stimulation; bars indicate inhibition. 
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